Severe acute respiratory syndrome (SARS) is the first pandemic of the 21st century ([@R1]). Since its recognition, 8437 individuals have been affected and 813 have died ([@R2]). Approximately 20--30% of patients required intensive care admission ([@R1]). Although there was a slight predominance of female SARS patients, possibly because of the overrepresentation of female healthcare workers ([@R1]), male SARS patients were more likely to suffer poor outcomes ([@R3]). In a major hospital outbreak in Hong Kong ([@R4]), 32% of male and 15% of female SARS patients required intensive care or died. Remarkably, similar demographic data were seen among SARS patients in the greater Toronto area, Canada, where 32% of males and 14% of females with SARS required intensive care or died ([@R5]). Karlberg et al. ([@R3]) studied the case fatality rates among all confirmed SARS patients documented in the Hong Kong SARS epidemic in 2003. The authors concluded that the mortality rates differed significantly between males and females, being 21.9% and 13.2%, respectively. The relative risk for death in males was 1.62 after adjustment for age. It is thus an intriguing coincidence that *ACE2*, the gene for the newly identified functional receptor for the SARS coronavirus, angiotensin-converting enzyme 2, maps to the X-chromosome (Xp22) ([@R6]).

ACE2 was first identified as a homolog of angiotensin-converting enzyme with zinc metalloproteinase activity ([@R7]). Many of its activities differ from those of angiotensin-converting enzyme ([@R8]). ACE2 has been found to be an important regulator of cardiac function ([@R9]). Since the identification of ACE2 as the functional receptor for the SARS coronavirus ([@R6]), efforts have been spent on characterizing its molecular interaction with the virus ([@R10])([@R11]). On the other hand, studies on mouse hepatitis virus, a group 2 coronavirus ([@R12]), demonstrated that allelic variants of viral receptor were associated with altered virus-binding activity, which mediated host susceptibility ([@R13]). Hence, it is plausible that genetic variants of *ACE2* may moderate the effects of SARS coronavirus infection and, possibly, gender-specific effects.

For this study, we obtained institutional ethics approval. We identified 103 single-nucleotide polymorphisms (SNPs) in *ACE2*, using the University of Washington and Fred-Hutchinson Cancer Research Center Variant Discovery Resource, SeattleSNPs ([@R14]). Two of the identified SNPs were located within the coding regions \[dbSNP identification nos. rs4646116 and rs4646179 ([@R15])\], whereas the remainder were located within the introns of *ACE2*. SNP validation by direct sequencing of the 101 noncoding SNPs was conducted with use of buffy coat DNA obtained from 10 female Chinese volunteers. This validation strategy allows the detection of SNPs with minor allele frequencies of at least 10% at 90% power. The two coding SNP loci were verified on buffy coat DNA from 20 female Chinese. Forty-eight pairs of primers were designed to facilitate direct sequencing of *ACE2* regions spanning all of the SNPs. Buffy coat DNA was extracted according to the Blood and Body Fluid Spin protocol in manufacturer's instructions for the QIAamp DNA Blood Mini Kit (Qiagen). DNA sequencing was performed by the dideoxy dye terminator method on an automated DNA sequencer (3100 Genetic Analyzer; Applied Biosystems) based on capillary electrophoresis. Sequences were edited and aligned, and comparisons were made with the SeqScape software (Applied Biosystems).

SNP validation confirmed sequence variations at five sites ([Table 1](#T1){ref-type="table"} ). All five SNP loci were noncoding. Both of the coding SNPs were shown to be nonpolymorphic among the 20 females. The positions and orientations of the five verified SNPs are illustrated in [Fig. 1](#F1){ref-type="fig"} . A case--control study was conducted to compare the frequencies of the five polymorphisms among 168 SARS patients (81 males and 87 females, among whom 30 males and 16 females had poor outcomes) from the Prince of Wales Hospital, Hong Kong ([@R4]), and 328 healthy volunteers (174 males and 154 females). All of the individuals studied were unrelated individuals of Chinese ethnicity. Genotype characterization was performed with TaqMan (Applied Biosystems) allelic discrimination assays on an ABI Prism 7900HT sequence detection system (Applied Biosystems). Each assay consisted of two allele-specific minor groove binding probes with different fluorescent labels, i.e., 6-carboxyfluorescein (FAM) or VIC™, designed for the discrimination of the two respective alleles at each SNP locus. The assays were set up according to the manufacturer's instructions (TaqMan Core PCR Kit; Applied Biosystems) in a reaction volume of 10 μL. The primers and fluorescent probes were used at concentrations of 900 and 200 nM, respectively. We used 10 ng of buffy coat DNA for amplification. The thermal profile consisted of an initial denaturation period for 10 min at 95 °C, followed by 40 cycles of denaturation at 92 °C for 15 s, and 1 min of combined annealing and extension at either 62 °C (SNPs rs2285666, rs4646142, and rs714205) or 65.5 °C (SNPs rs2106809 and rs2074192; [Table 1](#T1){ref-type="table"} ). The genotypes were scored with the SDS2.1 software.

###### 

Allele and genotype frequencies for the studied groups.

  A. Allele frequencies and χ^2^ analyses (*df* = 1)                                                                                                                                                                          
  ---------------------------------------------------- ---------- --------------------------- ---------- --------------------------- ---------- --------------------------- ---------- --------------------------- ---------- ---------------------------
  Minor allele                                         T                                      G                                      C                                      G                                      A          
  Controls (174 M/154 F)                               228 (47)                               224 (46)                               223 (46)                               215 (45)                               206 (43)   
  SARS patients^3^ (81 M/87 F)                         114 (45)   χ^2^ = 0.354; *P* = 0.552   111 (44)   χ^2^ = 0.470; *P* = 0.493   110 (43)   χ^2^ = 0.539; *P* = 0.463   111 (44)   χ^2^ = 0.047; *P* = 0.840   105 (41)   χ^2^ = 0.109; *P* = 0.741
  SARS patients with poor outcome^3^ (30 M/16 F)       30 (48)    χ^2^ = 0.000; *P* = 0.979   27 (44)    χ^2^ = 0.090; *P* = 0.765   27 (44)    χ^2^ = 0.072; *P* = 0.788   26 (42)    χ^2^ = 0.069; *P* = 0.793   25 (40)    χ^2^ = 0.051; *P* = 0.821
  Male SARS patients with poor outcome^4^ (n = 30)     13 (43)    χ^2^ = 0.590; *P* = 0.443   12 (40)    χ^2^ = 0.488; *P* = 0.485   12 (40)    χ^2^ = 0.410; *P* = 0.522   11 (37)    χ^2^ = 0.746; *P* = 0.388   11 (37)    χ^2^ = 0.401; *P* = 0.527
  Male controls (n = 174)                              92 (53)                                85 (49)                                84 (48)                                82 (47)                                78 (45)    
  Female SARS patients^4^ (n = 87)                     78 (45)    χ^2^ = 0.002; *P*= 0.962    77 (44)    χ^2^ = 0.008; *P* = 0.928   77 (44)    χ^2^ = 0.008; *P* = 0.928   78 (45)    χ^2^ = 0.064; *P* = 0.799   73 (42)    χ^2^ = 0.000; *P* = 0.991
  Female controls (n = 154)                            136 (44)                               139 (45)                               139 (45)                               133 (43)                               128 (42)   

  B. Genotype frequencies and χ^2^ analyses (*df* = 2)                                                                                                                                                                          
  ------------------------------------------------------ ---------- --------------------------- ---------- --------------------------- ---------- --------------------------- ---------- --------------------------- ---------- ---------------------------
  Genotype                                               CC/CT/TT                               AA/AG/GG                               GG/GC/CC                               CC/GC/GG                               GG/AG/AA   
  Female controls (n = 154)                              48/76/30   χ^2^ = 0.280; *P* = 0.878   44/81/29   χ^2^ = 0.099; *P* = 0.952   44/81/29   χ^2^ = 0.099; *P* = 0.952   44/87/23   χ^2^ = 1.102; *P* = 0.576   48/84/22   χ^2^ = 2.315; *P* = 0.314
  Female SARS patients^4^ (n = 87)                       25/46/16                               25/47/15                               25/47/15                               26/44/17                               1/39/17    

The SNP loci are identified according to the University of Washington *ACE2* sequence coordinates ([@R14]), and the relevant identification numbers at the SNP database ([@R15]) are in parentheses.

Genotyping performed with Applied Biosystems Assays-on-Demand™, C2551616_1 and C2551626_1.

The combined male (M) and female (F) control group is used as the comparison group.

The control group of the same gender is used as the comparison group. Because males are hemizygous for *ACE2*, the number of alleles is equivalent to the number of males. Because females have two X chromosomes, the number of alleles is twice the number of females. At each SNP locus, only the minor allele frequency is listed.

![Schematic illustration of the genomic organization of *ACE2* and positions of the studied SNP loci.\
*ACE2* contains 18 exons. Each exon is represented by an *open box*. The *arrows* mark the positions of the five verified SNPs. All five SNPs are located within noncoding regions of *ACE2*. The individual SNPs are named according to their identification numbers registered at the SNP database (dbSNP) ([@R15]).](zcy0090469890001){#F1}

The allele frequencies for the SARS and control groups are listed in [Table 1](#T1){ref-type="table"} . When we used the allele frequencies obtained from the control group, the group sample size provided a power of at least 80% for the determination of a genetic factor that contributes 50% increased likelihood toward the development of SARS or poor outcome with 95% confidence. Statistical significance among groups was examined by the χ^2^ test for each SNP locus (SigmaStat, Ver. 3.0; SPSS). Statistical significance was denoted by a two-tailed *P* \<0.05. No significant difference was observed in the allele distributions between the female and male controls (data not shown), between the SARS cases and controls, between SARS cases with poor outcomes and controls, between the male SARS patients with poor outcome and the male controls, or between the female SARS patients and female controls ([Table 1](#T1){ref-type="table"} ). The observed genotype distributions for each of the five loci among the female controls did not deviate significantly from those expected from the Hardy--Weinberg equilibrium. The genotype frequencies for each of the five SNP loci were not statistically significantly different between the female SARS patients and the female controls. Because males are hemizygous for *ACE2*, the genotype frequency is equivalent to the allele frequency.

We therefore conclude that although ACE2 serves functionally as the receptor for entry of the SARS coronavirus into human host cells, the evidence provided by this study does not support an association between its common genetic variants and SARS susceptibility or outcome. Despite its X-chromosome location, poor outcomes in male SARS patients do not appear to be related to genetic variants of *ACE2*.
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